

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT3787634

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
Alisha B. Arrigo	02/24/2016
Derrick Juengst	02/24/2016
Khalid Shah	03/11/2016
RECEIVING PARTY DATA	
Name:	ARRAY BIOPHARMA, INC.
Street Address:	3200 WALNUT ST.
City:	BOULDER
State/Country:	COLORADO
Postal Code:	80301
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	14943014
CORRESPONDENCE DATA	
Fax Number:	(877)769-7945
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	(612) 337-5070
Email:	jwright@fr.com
Correspondent Name:	ANGELA D. FOLLETT
Address Line 1:	FISH & RICHARDSON P.C.
Address Line 2:	P.O.BOX 1022
Address Line 4:	MINNEAPOLIS, MINNESOTA 55440-1022
ATTORNEY DOCKET NUMBER:	40449-0010001
NAME OF SUBMITTER:	JILL A. WRIGHT
SIGNATURE:	/Jill A. Wright/
DATE SIGNED:	03/17/2016
Total Attachments: 5	
source=40449.0010001Assignment#page1.tif	
source=40449.0010001Assignment#page2.tif	
source=40449.0010001Assignment#page3.tif	

source=40449.0010001Assignment#page4.tif

source=40449.0010001Assignment#page5.tif

ASSIGNMENT


For valuable consideration, the receipt of which we acknowledge, and intending to be bound legally, we, ALISHA B. ARRIGO, DERRICK JUENGST, and KHALID SHAH, each individually assign to ARRAY BIOPHARMA, INC., a corporation formed under the laws of Delaware and having a principal place of business at 3200 Walnut St., Boulder, CO 80301, and its successors, transferees, and assignees (collectively the "Assignee"), all of our individual and joint right, title, and interest throughout the world in the subject matter (the "Subject Matter") of a patent application that names us as inventors, is titled "CRYSTALLINE FORM OF (S)-N-(5-((R)-2-(2,5-DIFLUOROPHENYL)-PYRROLIDIN-1-YL)-PYRAZOLO[1,5-A]PYRIMIDIN-3-YL)-3-HYDROXYPYRROLIDINE-1-CARBOXAMIDE HYDROGEN SULFATE," and was filed in the United States Patent and Trademark Office on November 16, 2015, as application 14/943,014, International Application No. PCT/US2015/060953 filed November 16, 2015 and U.S. Provisional Application No. 62/169,545 filed June 1, 2015 (the "Application").

This Assignment assigns (a) the Application and all other applications that may be made for, and all patents, utility models, design registrations, and other rights of exclusion and inventors' certificates for, any of the Subject Matter (collectively the "Applications and Granted Rights") in every country or region, (b) the right to claim priority based on and the benefit of the filing date of any of the Applications and Granted Rights under the International Convention for the Protection of Industrial Property, the Patent Cooperation Treaty, the European Patent Convention, and all other applicable treaties or conventions, and (c) the right to pursue, collect, and retain in the Assignee's name or otherwise, damages and any other remedies arising from any past, present, or future infringement of the Subject Matter, the Applications and Granted Rights, and any other rights assigned by this Assignment.

We authorize the Assignee to apply for and pursue protection for any or all of the Subject Matter, the Applications and Granted Rights, and any other rights assigned by this Assignment in all countries, regions, and territories of the world, in our names or in the Assignee's name.

We represent and warrant that we have the right and power to make this Assignment and that we have not made and will not make any other assignment that conflicts with this Assignment.

We will communicate to the Assignee (or at the request of the Assignee to other parties) all known facts in any form relating to the Subject Matter, will execute and provide all oaths and declarations, statements, testimony, assignments, powers of attorney, applications, and documents, and will perform all other lawful acts necessary or desirable to secure fully to the Assignee the rights, titles, and interests assigned by this Assignment.


Alisha B. Arrigo

Date: 2-24-2016

State of Colorado

County of Boulder

The foregoing instrument was acknowledged before me this Feb. 24, 2016 by


Alisha B. Arrigo

M. E. G. 502

(Notary's official signature)

10/15/2019

(Commission expiration date)



Derrick Juengst
Derrick Juengst

Date: 02/24/16


State of Colorado

County of Boulder

The foregoing instrument was acknowledged before me this Feb. 24, 2016 by
Derrick Juengst.

Susan E. Elsberry
(Notary's official signature)

10/15/2019
(Commission expiration date)



Khalid Shah
Khalid Shah

Date: 11th MAR, 2016

A notary public or other officer completing this certificate verifies only the identity of the individual who signed the document to which this certificate is attached, and not the truthfulness, accuracy, or validity of that document.

State of California
County of San Mateo


On March 11, 2016 before me, Nancy Simmons, Notary Public
(insert name and title of the officer)

personally appeared Khalid Shah
who proved to me on the basis of satisfactory evidence to be the person whose name is subscribed to the within instrument and acknowledged to me that he executed the same in his authorized capacity, and that by his signature on the instrument the person, or entity upon behalf of which the person acted, executed the instrument.

I certify under PENALTY OF PERJURY under the laws of the State of California that the foregoing paragraph is true and correct.

WITNESS my hand and official seal.

Signature Nancy Simmons



The Assignee hereby acknowledges and accepts the foregoing assignment.

Assignee: ARRAY BIOPHARMA, INC.

Signature: [Signature]

Date: 3/11/2014

Name: John R. Moore

Title: VP + General Counsel


State of Colorado

County of Boulder

The foregoing instrument was acknowledged before me this March 11, 2014 by
John R. Moore.

[Signature]
(Notary's official signature)

10/15/2019
(Commission expiration date)



61283450.doc